3-DEAZAGUANINE, A CANDIDATE DRUG FOR THE CHEMOTHERAPY OF BREAST CARCINOMAS

Abstract

3-Deazaguanine (3-DG) is a new purine antagonist that is active against slow- and rapid-growing solid experimental tumors, especially those that are models for human breast carcinomas. These tumors include mammary adenocarcinomas [rat] 13762, [rat] R3230AC and [mouse] C3H/16C. 3-DG also showed positive activity against [mouse] leukemias L1210 and L1210/araC, [mouse] adenocarcinoma 755 and [mouse] EMT-6 mammary adenocarcinoma. On the basis of its activity against these tumors, 3-DG is to undergo clinical trials.